SEEL
Income statement / Annual
Last year (2023), Seelos Therapeutics, Inc.'s total revenue was $2.20 M,
and the percentage change from the previous year is not available.
In 2023, Seelos Therapeutics, Inc.'s net income was -$37.88 M.
See Seelos Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.20 M |
$0.00 |
$0.00 |
$0.00 |
$375.00 K |
$0.00 |
$0.00 |
$5.76 M |
$4.84 M |
$9.26 M |
| Cost of Revenue |
$30.12 M
|
$53.00 K
|
$0.00
|
$0.00
|
$22.56 M
|
$0.00
|
$117.00 K
|
$3.89 M
|
$922.00 K
|
$918.00 K
|
| Gross Profit |
-$27.91 M
|
-$53.00 K
|
$0.00
|
$0.00
|
-$22.19 M
|
$0.00
|
-$117.00 K
|
$1.87 M
|
$3.92 M
|
$8.34 M
|
| Gross Profit Ratio |
-12.67
|
0
|
0
|
0
|
-59.17
|
0
|
0
|
0.32
|
0.81
|
0.9
|
| Research and Development Expenses |
$30.12 M
|
$58.62 M
|
$46.65 M
|
$10.98 M
|
$22.56 M
|
$1.22 M
|
$3.46 M
|
$6.83 M
|
$14.65 M
|
$21.29 M
|
| General & Administrative Expenses |
$12.59 M
|
$12.30 M
|
$15.02 M
|
$7.78 M
|
$7.56 M
|
$7.93 M
|
$7.21 M
|
$8.43 M
|
$10.52 M
|
$11.42 M
|
| Selling & Marketing Expenses |
-$57.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.53 M
|
$12.30 M
|
$15.02 M
|
$7.78 M
|
$7.56 M
|
$7.93 M
|
$7.21 M
|
$8.43 M
|
$10.52 M
|
$11.42 M
|
| Other Expenses |
$0.00
|
$0.00
|
$230.00 K
|
$0.00
|
-$375.00 K
|
$1.00 K
|
$77.00 K
|
-$22.00 K
|
-$64.00 K
|
$82.00 K
|
| Operating Expenses |
$12.59 M
|
$70.92 M
|
$61.67 M
|
$18.76 M
|
$29.75 M
|
$9.15 M
|
$10.67 M
|
$15.27 M
|
$25.17 M
|
$30.90 M
|
| Cost And Expenses |
$42.70 M
|
$70.92 M
|
$61.67 M
|
$18.76 M
|
$29.75 M
|
$9.15 M
|
$10.67 M
|
$19.16 M
|
$26.09 M
|
$31.82 M
|
| Interest Income |
$198.00 K
|
$121.00 K
|
$113.00 K
|
$45.00 K
|
$151.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$75.00 K
|
$14.00 K
|
$1.60 M
|
$164.00 K
|
$29.00 K
|
$0.00
|
$83.00 K
|
$1.02 M
|
$845.00 K
|
$339.00 K
|
| Depreciation & Amortization |
$57.00 K
|
$53.00 K
|
$61.67 M
|
$18.76 M
|
$41.00 K
|
$41.00 K
|
$117.00 K
|
$106.00 K
|
$300.00 K
|
$170.00 K
|
| EBITDA |
-$37.75 M |
-$73.47 M |
$0.00 |
$0.00 |
-$29.33 M |
-$3.14 M |
-$10.56 M |
-$6.11 M |
-$17.83 M |
-$21.97 M |
| EBITDA Ratio |
-17.14
|
0
|
0
|
0
|
-78.21
|
0
|
0
|
-1.06
|
-3.68
|
-2.37
|
| Operating Income Ratio |
-18.38
|
0
|
0
|
0
|
-79.33
|
0
|
0
|
-2.33
|
-4.41
|
-2.44
|
| Total Other Income/Expenses Net |
$2.62 M
|
-$2.62 M
|
-$4.38 M
|
-$342.00 K
|
-$21.51 M
|
$5.74 M
|
-$1.08 M
|
$5.96 M
|
$2.33 M
|
$82.00 K
|
| Income Before Tax |
-$37.88 M
|
-$73.53 M
|
-$66.05 M
|
-$19.10 M
|
-$50.88 M
|
-$9.22 M
|
-$11.75 M
|
-$7.43 M
|
-$19.02 M
|
-$22.48 M
|
| Income Before Tax Ratio |
-17.2
|
0
|
0
|
0
|
-135.68
|
0
|
0
|
-1.29
|
-3.93
|
-2.43
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$497.00 K
|
-$70.00 K
|
$0.00
|
$1.00 M
|
$0.00
|
$0.00
|
| Net Income |
-$37.88 M
|
-$76.14 M
|
-$67.53 M
|
-$19.22 M
|
-$50.38 M
|
-$9.24 M
|
$321.00 K
|
-$7.43 M
|
-$19.02 M
|
-$21.79 M
|
| Net Income Ratio |
-17.2
|
0
|
0
|
0
|
-134.35
|
0
|
0
|
-1.29
|
-3.93
|
-2.35
|
| EPS |
-7.73 |
-21.48 |
-22.29 |
-12.88 |
-74.43 |
-42.88 |
1.49 |
-67.41 |
-108.23 |
-165 |
| EPS Diluted |
-7.73 |
-21.48 |
-22.29 |
-12.88 |
-74.43 |
-42.88 |
1.49 |
-67.41 |
-107.24 |
-165 |
| Weighted Average Shares Out |
$4.90 M
|
$3.54 M
|
$3.03 M
|
$1.49 M
|
$676.96 K
|
$215.52 K
|
$215.52 K
|
$110.27 K
|
$175.77 K
|
$132.04 K
|
| Weighted Average Shares Out Diluted |
$4.90 M
|
$3.54 M
|
$3.03 M
|
$1.49 M
|
$676.96 K
|
$215.52 K
|
$215.52 K
|
$110.27 K
|
$177.39 K
|
$132.04 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
